老年药物性肝损伤患者临床特征分析*

doi:10.3969/j.issn.1672-5069.2024.04.014

摘要/Abstract

摘要： 目的分析老年药物性肝损伤(DILI)患者的临床特征,以为临床干预提供依据。方法 2018年12月～2024年2月我院老年医学科诊治的老年多种疾病患者181例,常规行临床分型和疾病程度分度。应用单因素和多因素Logistic回归分析影响DILI病情严重程度的危险因素。结果在181例老年患者中,发现DILI者44例(24.3%),其中肝细胞损伤型28例,胆汁淤积型12例,混合型4例;轻度25例,中度10例,重度8例,死亡1例;可疑药物为中草药占27.3%,保健类药物占22.7%,内分泌系统疾病用药占13.6%,心脑血管疾病用药占11.4%,等; DILI组年龄为72(66,76)岁,显著大于非DILI组【67(65,69),P<0.05】,多种疾病、饮酒、脂肪肝和高脂血症占比分别为79.6%、27.3%、56.8%和84.1%,显著高于非DILI组(分别为11.7%、3.6%、12.4%和8.7%,均P<0.05);9例≥3级肝损伤患者年龄为73(67,75)岁,显著大于35例≤2级肝损伤者【67(66,70)岁,P<0.05】,饮酒、多种疾病和合并脂肪肝占比分别为88.9%、100.0%和88.9%,均显著大于≤2级肝损伤者(分别为11.4%,74.3%和48.6%,均P<0.05),多因素Logistic回归分析表明,高龄【OR:1.67,95%CI:1.26～3.05】、饮酒【OR:2.43,95%CI:1.35～3.17】和脂肪肝【OR:2.14,95%CI:1.50～4.75】均是影响老年DILI患者病情严重程度的独立危险因素(P<0.05)。结论中草药、保健类药物、内分泌和心脑血管系统疾病用药容易导致老年基础疾病多的患者发生DILI,戒酒、降低脂肪肝程度和控制好疾病发作可能减轻DILI严重程度,值得临床深入研究。

关键词: 药物性肝损伤, 基础疾病, 危险因素, 特征, 老年

Abstract: Objective This study was conducted to summarize clinical feature of elderly patients with drug-induced liver injury (DILI), and to investigate risk factors impacting severity of liver illness. Methods 181 elderly patients with various underlying diseases were encountered in our hospital between December 2018 and February 2024, and DILI was routinely diagnosed, catalogued and liver injury determined. Univariate and multivariate Logistic regression analysis was applied to find risk factors for liver injuries. Results Of 181 elderly patients, DILI was diagnosed in 44 cases(24.3%), including hepatocellular injury in 28 cases, cholestasis in 12 cases and mixed type in 4 cases; there were mild liver injury in 25 cases, moderate in 10 cases, severe in 8 cases and dead in 1 cases; suspected herbal medicines accounted for 27.3%, health care agents for 22.7%, agents for endocrine diseases for 13.6% and medicines for cardiovascular diseases for 11.4%, etc; ages in patients with DILI was 72(66, 76)yr, much greater than [67(65, 69)yr, P<0.05] in patients without DILI, percentages of multiple concurrent underlying diseases, alcohol abuse, fatty liver and hyperlipidemia were 79.6%, 27.3%, 56.8% and 84.1%, all much higher than 11.7%, 3.6%, 12.4% and 8.7% (all P<0.05) in patients without DILI; ages in 9 patients with liver injury grade 3 or more was 73(67, 75) yr, much older than [67(66, 70)yr, P<0.05] in 35 patients with liver injury of grade 2 or less, percentages of ethanol intake, multiple underlying diseases and concurrent fatty liver was 88.9%, 100.0% and 88.9%, all significantly greater than 11.4%, 74.3% and 48.6% (all P<0.05) in patients with grade 2 or less liver injuries; multivariate Logistic regression analysis showed that elderly [OR:1.67, 95%CI:1.26-3.05], alcohol abuse [OR:2.43, 95%CI:1.35-3.17] and fatty liver [OR:2.14, 95%CI:1.50-4.75] were all the risk factors impacting severity of liver injuries in elderly patients with DILI(P<0.05). Conclusion Herbal medicine, health care drugs, agents for endocrine and cardiovascular diseases could lead to DILI occurrence in elderly patients with multiple system diseases, in which drug-drug interactions might involve in this setting, and clinicians should carefully deal with underlying diseases, and prescribe medicines as necessary as possible.

Key words: Drug-induced liver injury, Underlying diseases, Clinical feature, Risk factors, Elderly

李勇, 张蕾, 吴幸福. 老年药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 547-550.

Li Yong, Zhang Lei, Wu Xingfu. Clinical feature of elderly patients with drug-induced liver injury: An analysis of 44 cases[J]. Journal of Practical Hepatology, 2024, 27(4): 547-550.

参考文献

[1] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology, 2019, 156(8):2230-2241,e11.
[2] Zhou Y, Yang L, Liao Z, et al. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol, 2013, 25(7):825-829.
[3] Zhang C, Wu Y, Yuan S, et al. Characteristics of drug-induced liver injury in Northeast China: Disease spectrum and drug types. Dig Dis Sci, 2020, 65(11):3360-3368.
[4] Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol, 2016, 65(3):532-542.
[5] Weersink RA, Alvarez-Alvarez I,Medina-Cáliz I, et al. Clinical characteristics and outcome of drug-induced liver injury in the older patients: From the young-old to the oldest-old. Clin Pharmacol Ther, 2021, 109(4):1147-1158.
[6] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志, 2015, 23(11): 810-820.
[7] 肖亮. 肝脏穿刺活检湘雅专家共识. 中国普通外科杂志, 2021, 30(1):1-8.
[8] Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut, 2020, 69(8):1382-1403.
[9] Xiong YT, Wang JF, Niu XX, et al. Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury. Front Pharmacol, 2023, 14:1071709.
[10] Danjuma MI, Almasri H, Alshokri S, et al. Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score. BMC Geriatr, 2020, 20(1):346.
[11] Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol, 2015, 63(2):503-514.
[12] Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology, 2013, 144(7):1419,e20.
[13] Koch L. Therapy: Propylthiouracil use associated with severe hepatotoxicity in children. Nat Rev Endocrinol, 2010, 6(8):416.
[14] Allard J, Le Guillou D, Begriche K, et al. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Adv Pharmacol, 2019, 85:75-107.
[15] Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis, 2014, 18(1):165-178.
[16] 刘如玉, 路遥, 申戈, 等. HBeAg 阴性初治慢乙肝患者恩替卡韦4年抗病毒治疗FIB-4评分动态变化研究. 中华实验和临床病毒学杂志, 2020, 34(1): 51-56.
[17] 李晓芸,钟巍,茅益民. 他汀类药物相关药物性肝损伤. 中华肝脏病杂志, 2023, 31(6):659-663.
[18] 林云霞,何晓彬. 药物性肝损伤的临床特点及危险因素分析. 临床肝胆病杂志, 2018, 34(6):1237-1241.
[19] 王焱, 周静, 韩军. 自身免疫性肝炎和药物性肝损伤患者临床病理特征分析. 实用肝脏病杂志, 2023, 26(2):218-221.
[20] Puri M. Automated machine learning diagnosticsupport system as a computational biomarker for detecting drug-induced liver injury patterns in whole slide liver pathology images. Assay Drug Dev Technol, 2020, 18(1):1-10.

老年药物性肝损伤患者临床特征分析^*

Clinical feature of elderly patients with drug-induced liver injury: An analysis of 44 cases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	廖敏君, 饶慧瑛. 脂肪性肝病相关肝细胞癌筛查和监测策略[J]. 实用肝脏病杂志, 2024, 27(4): 484-487.
[2]	张丽, 陈雅雯, 盖琳, 邱红, 甄鑫, 常静霞. 乙型肝炎病毒/丙型肝炎病毒共同感染患者临床特征及其对抗病毒治疗应答反应研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 523-526.
[3]	李开楊, 赵琦, 黄敬, 唐云, 蔺晓源, 刘杰民, 杨梅. 中国临床试验注册中心注册的非酒精性脂肪性肝病临床试验特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 531-534.
[4]	潘劲劲, 谢琴秀, 许夕海, 郜玉峰, 李家斌. 药物性肝损伤患者血清抗核抗体阳性临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 543-546.
[5]	吴鹤林, 吴卉卉, 沈春林. 肝脏炎性假瘤增强CT扫描表现^*[J]. 实用肝脏病杂志, 2024, 27(4): 623-626.
[6]	农晓黎, 陈菲, 詹浩洪, 罗婷, 曾碧丹. 体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 353-356.
[7]	曹焱芬, 邹昊轩, 谢艳. 体检人群血浆致动脉粥样硬化指数诊断代谢相关脂肪性肝病效能分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 361-365.
[8]	姜正伟, 周冰清, 汤洁, 蒋蓓莉. 血清抗糖蛋白210抗体阳性的原发性胆汁性胆管炎患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 378-381.
[9]	郎平, 崔闪闪, 赵艳. 药物性肝损伤患者外周血淋巴细胞谱和免疫检查点受体及其配体表达变化分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 382-385.
[10]	高萍, 高学松, 张亦瑾, 孙磊, 刘楠, 李洪杰, 刘亚平, 高丽丽, 段雪飞. 8例血色病患者临床与基因突变特征分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 386-389.
[11]	王修琪, 张裕, 吴一凡, 董成宾, 岳振东, 王成. TIPS术治疗的肝硬化患者肝性脊髓病临床特征及其影响因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 410-413.
[12]	朱春芬, 任春霖, 郭霞. 肝硬化性心肌病患者临床特点、心电图表现和危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 414-417.
[13]	倪裕丰, 倪国英, 杨志勇. 肝细胞癌组织BCLAF1和TCF3 RNA水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 418-421.
[14]	师玉, 孟令辉, 王禄马. 肝内胆管细胞癌增强CT扫描特征及其诊断价值分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 446-449.
[15]	师阿盟, 何鑫, 王莹, 姜珏, 周琦, 王倩, 史海涛, 董蕾. 非肥胖人群胆结石检出率与危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 458-461.